National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

  • Pertuzumab (Perjeta®) - August 28, 2013

    The NCPE believes that pertuzumab in combination with trastuzumab and docetaxel is not a cost-effective treatment for adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy.

  • Crizotinib (Xalkori®) - August 27, 2013

    The NCPE do not consider Crizotinib (Xalkori) a cost-effective treatment for adult patients with previously treated ALK positive advanced non small cell lung cancer (NSCLC).

  • Ruxolitinib (Jakavi®) - July 16, 2013

    The NCPE do not consider ruxolitinib to be a cost effective treatment of splenomegaly or disease-related symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

  • Apixaban (Eliquis®) for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation - May 21, 2013

    The NCPE conclude that apixaban can be considered cost effective for the prevention of stroke and systemic embolism in people with non valvular atrial fibrillation.

  • Omega-3-acid ethyl esters (Omacor®) - April 22, 2013

    The NCPE believe that Omacor® is not a cost-effective adjuvant treatment for patients post-myocardial infarction in the Irish Healthcare Setting. The cost effectiveness of Omacor® for treatment of endogenous hypertriglyceridaemia as a supplement to diet has not been demonstrated.

  • Pirfenidone (Esbriet®) - March 20, 2013

    The NCPE believe that, at the submitted price, pirfenidone is not cost-effective for the treatment of patients with mild to moderate Idiopathic Pulmonary Fibrosis.

  • Fidaxomicin (Dificlir®) - February 5, 2013

    Fidaxomicin (Dificlir®) may be considered a cost-effective use of resources. It should be prescribed according to the recommendations outlined in the recently updated National Clostridium difficile Guidelines (due to be completed in February 2013

  • Ivacaftor (Kalydeco®) - February 1, 2013

    The NCPE recommendation on ivacaftor (Kalydeco®), led to follow-up discussions between the HSE CPU and the company, Vertex Pharmaceuticals, resulting in a positive recommendation on the provision of the drug for Irish CF patients, whilst at the same time significantly reducing the budget impact of the drug.

  • Bendamustine (Levact®) - December 13, 2012

    The NCPE recommends reimbursement of bendamustine (Levact®) for patients unable to tolerate fludarabine/clyclophosphamide.

  • Eribulin (Halaven®) - December 7, 2012

    The NCPE believe that, at the submitted price, eribulin (Halaven®) is not cost effective for the treatment of patients with locally advanced breast cancer or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease.